Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa

Kazuki Fujimoto; Narumi Maki; Daisuke Hashiba; Toshifumi Maeyama; Ryosuke Nakagawa; Hajime Arai; Seiji Ohtori

doi:10.1016/j.afos.2023.10.001

Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa

Osteoporos Sarcopenia. 2023 Dec;9(4):137-141. doi: 10.1016/j.afos.2023.10.001. Epub 2023 Nov 18.

Authors

Kazuki Fujimoto¹, Narumi Maki¹, Daisuke Hashiba¹, Toshifumi Maeyama¹, Ryosuke Nakagawa¹, Hajime Arai¹, Seiji Ohtori²

Affiliations

¹ Department of Orthopaedic Surgery, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa City, Chiba, 272-8516, Japan.
² Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

Abstract

Objectives: This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism.

Methods: In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and anorexia nervosa with fragility fractures. BMD and bone turnover marker changes were investigated at 6 months and 1 year after administering romosozumab.

Results: BMD increased and high-turnover bone metabolism decreased 6 months and 1 year after administering romosozumab.

Conclusions: Romosozumab is useful for treating osteoporosis in patients with anorexia nervosa.

Keywords: Anorexia nervosa; Anti-sclerostin antibody; Bone metabolism; Secondary osteoporosis.